TheStreet cut shares of Repligen Corporation (NASDAQ:RGEN) from a b- rating to a c rating in a report published on Monday.

Several other research analysts have also recently weighed in on RGEN. William Blair initiated coverage on Repligen Corporation in a research report on Friday, July 21st. They set an outperform rating for the company. BidaskClub cut Repligen Corporation from a strong-buy rating to a buy rating in a research report on Monday, July 31st. Zacks Investment Research upgraded Repligen Corporation from a hold rating to a buy rating and set a $46.00 price target for the company in a research report on Saturday, August 12th. Jefferies Group LLC reiterated a hold rating and set a $40.00 price target on shares of Repligen Corporation in a research report on Thursday, September 14th. Finally, Stephens reiterated an overweight rating and set a $50.00 price target on shares of Repligen Corporation in a research report on Tuesday, September 26th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of Buy and an average target price of $44.67.

Repligen Corporation (RGEN) opened at $32.61 on Monday. The firm has a market capitalization of $1,460.74, a P/E ratio of 57.81, a P/E/G ratio of 2.23 and a beta of 1.05. Repligen Corporation has a 12-month low of $28.48 and a 12-month high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.04. The company had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. Repligen Corporation had a return on equity of 7.57% and a net margin of 16.93%. Repligen Corporation’s quarterly revenue was up 48.2% on a year-over-year basis. During the same period last year, the business earned $0.08 earnings per share. analysts expect that Repligen Corporation will post 0.6 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Repligen Corporation (RGEN) Downgraded by TheStreet” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/16/repligen-corporation-rgen-downgraded-by-thestreet.html.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of Repligen Corporation by 3.7% in the second quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock valued at $200,355,000 after buying an additional 170,551 shares in the last quarter. TimesSquare Capital Management LLC increased its position in shares of Repligen Corporation by 19.8% in the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock valued at $97,851,000 after buying an additional 390,545 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Repligen Corporation by 9.7% in the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock valued at $82,233,000 after buying an additional 175,191 shares in the last quarter. Conestoga Capital Advisors LLC increased its position in shares of Repligen Corporation by 12.5% in the third quarter. Conestoga Capital Advisors LLC now owns 1,453,232 shares of the biotechnology company’s stock valued at $55,688,000 after buying an additional 161,427 shares in the last quarter. Finally, FMR LLC increased its position in shares of Repligen Corporation by 6.2% in the second quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock valued at $55,285,000 after buying an additional 78,060 shares in the last quarter. Institutional investors and hedge funds own 96.47% of the company’s stock.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen Corporation (NASDAQ:RGEN)

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.